Merck right now is going to fight cases. But obviously, if there's thousands and thousands of cases, they'll end up not being able to fight all of them. They will have to settle some of them.
I think they're relatively cheap. What we saw was a big run-up toward April, and now we're seeing a little more profit-taking.
If I was one of the attorneys suing Merck, I would be very excited about this. It would imply that the company actively omitted data in a public forum, trying to make their product look better.
Any antidepressant drug ends up being a $2 billion drug at least, but we've seen the depression market really slow down. It's a big, [but] lackluster market.
It makes sense, after losing a big case like the one in Texas. But it doesn't sound like many cases will fall into that category.
I would expect costs to rise as the year goes on. They shifted some savings into this quarter.
Most of the bad things are happening now, and things do get brighter at the end of the decade. They are still a lot people on the sidelines who would rather wait and miss a little bit of run-up, but get confirmation [later on] that those stocks are going to strengthen.
Other companies facing top line pressures are going to have to cut costs.
Copyright © 2024 Electric Goat Media. All Rights Reserved.